Rice Hall James & Associates LLC Purchases Shares of 18,833 Repligen Corporation $RGEN

Rice Hall James & Associates LLC acquired a new position in shares of Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,833 shares of the biotechnology company’s stock, valued at approximately $2,570,000.

Other hedge funds also recently modified their holdings of the company. Measured Wealth Private Client Group LLC bought a new position in shares of Repligen in the third quarter valued at approximately $29,000. Bayforest Capital Ltd bought a new stake in Repligen during the 4th quarter worth approximately $32,000. Rachor Investment Advisory Services LLC bought a new stake in Repligen during the 4th quarter worth approximately $33,000. Los Angeles Capital Management LLC acquired a new stake in Repligen during the 4th quarter valued at $36,000. Finally, Farther Finance Advisors LLC increased its holdings in Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 128 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Transactions at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Wolfe Research assumed coverage on Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price objective on the stock. Evercore restated an “outperform” rating and issued a $160.00 target price on shares of Repligen in a research note on Monday, July 6th. Benchmark raised Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. Zacks Research upgraded shares of Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Finally, Wells Fargo & Company increased their price objective on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Repligen has a consensus rating of “Buy” and a consensus target price of $166.43.

Repligen Trading Down 1.7%

RGEN stock opened at $166.15 on Wednesday. The company has a market cap of $9.38 billion, a P/E ratio of 227.60, a PEG ratio of 3.04 and a beta of 1.03. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $175.77. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The business has a fifty day moving average of $144.29 and a 200-day moving average of $131.18.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities research analysts expect that Repligen Corporation will post 2.06 EPS for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.